Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of$8.43. The reported figure was down 14% from $9.55 reported in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The decline in the bottom line can be attributed to lower revenues and higher operating expenses.Total revenues decreased 4$3 billion due to lower sales of lead drug Eylea. Reven ...